# Ascentage Pharma Group Inc. clinical trials: 53 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 53 trials with Ascentage Pharma Group Inc. as lead sponsor, 22 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Ascentage Pharma Group Inc.: 53 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/ascentage-pharma-group-inc

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 53
- Recruiting or not yet: 22
- Read on: November 19, 2026

## Trials

The 25 newest of 53, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| February 20, 2026 | NCT07424833 | A Study of APG-3288 in Relapsed/Refractory Blood Cancers | Ascentage Pharma Group Inc. | Phase 1 | Recruiting | Relapsed/Refractory Hematological Malignancies, Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic... | 180 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07424833) |
| December 15, 2025 | NCT07282093 | Pharmacokinetics of Olverembatinib in Participants With Hepatic Impairment | Ascentage Pharma Group Inc. | Phase 1 | Recruiting | Pharmacokinetic, Olverembatinib | 48 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07282093) |
| November 13, 2024 | NCT06687070 | APG-2449 Monotherapy or in Combination With PLD in Patients With Platinum-resistant Recurrent OC or Advanced ST | Ascentage Pharma Group Inc. | Phase 1 | Recruiting | Platinum-resistant Recurrent Ovarian Cancer, Advanced Solid Tumor | 90 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06687070) |
| October 15, 2024 | NCT06641414 | Lisaftoclax (APG-2575) Combined With Azacytidine (AZA) in the Treatment of Patients With Higher-risk Myelodysplastic Syndrome (GLORA-4). | Ascentage Pharma Group Inc. | Phase 3 | Recruiting | Higher-risk Myelodysplastic Syndrome | 490 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06641414) |
| October 15, 2024 | NCT06640361 | A Study of Olverembatinib in SDH-deficient GIST. | Ascentage Pharma Group Inc. | Phase 3 | Recruiting | GIST | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06640361) |
| May 21, 2024 | NCT06423911 | Study of Olverembatinib (HQP1351) in Patients With CML-CP | Ascentage Pharma Group Inc. | Phase 3 | Recruiting | Chronic Myeloid Leukemia, CML, CML, Chronic Phase | 333 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06423911) |
| April 29, 2024 | NCT06389292 | A Pivotal Study of APG-2575 (Lisaftoclax) Combined With Azacitidine in the Treatment of Acute Myeloid Leukemia | Ascentage Pharma Group Inc. | Phase 3 | Recruiting | Acute Myeloid Leukemia | 486 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06389292) |
| March 20, 2024 | NCT06319456 | A Study of Lisaftoclax (APG-2575) Combined With Acalabrutinib Versus Immunochemotherapy for Newly Diagnosed CLL/SLL. | Ascentage Pharma Group Inc. | Phase 3 | Recruiting | CLL/SLL | 344 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06319456) |
| December 27, 2023 | NCT06182969 | A Study of APG-2575 in Patients With Mild-to-moderate Systemic Lupus Erythematosus. | Ascentage Pharma Group Inc. | Phase 1/2 | Recruiting | SLE | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06182969) |
| October 27, 2023 | NCT06104566 | Global Trial in APG2575 for Patients With CLL/SLL | Ascentage Pharma Group Inc. | Phase 3 | Recruiting | CLL/SLL | 400 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06104566) |
| September 22, 2023 | NCT06051409 | A Study of Olverembatinib in Patients With Newly Diagnosed Ph+ ALL (POLARIS-1) | Ascentage Pharma Group Inc. | Phase 3 | Recruiting | Ph+ ALL, Leukemia, Lymphoblastic, Acute, Philadelphia-Positive | 350 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06051409) |
| March 17, 2023 | NCT05773586 | A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Efficacy of APG-5918. | Ascentage Pharma Group Inc. | Phase 1 | Recruiting | Anemia | 105 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05773586) |
| January 27, 2023 | NCT05701306 | APG-115 Alone or in Combination With APG-2575 in Recurrent or Refractory Neuroblastoma or Solid Tumors | Ascentage Pharma Group Inc. | Phase 1/2 | Recruiting | Neuroblastoma, Solid Tumor | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05701306) |
| October 26, 2022 | NCT05594758 | Named Patient Program for Olverembatinib (HQP1351) | Ascentage Pharma Group Inc. | Not applicable | Available |  | Not listed | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05594758) |
| August 26, 2022 | NCT05517616 | The Absorption, Metabolism and Excretion of \[14C\]APG-2575 in Healthy Subjects | Ascentage Pharma Group Inc. | Phase 1 | Completed | Pharmacokinetics | 6 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05517616) |
| June 10, 2022 | NCT05415098 | Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or Lymphomas | Ascentage Pharma Group Inc. | Phase 1 | Unknown | Nasopharyngeal Carcinoma, Castrate Resistant Prostate Cancer, Gastric Cancer, Ovarian Clear Cell Carcinoma... | 90 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05415098) |
| January 11, 2022 | NCT05186012 | APG-1252 Monotherapy or in Combination With Other Therapeutic Agent in Subjects With Relapsed or Refractory Non-Hodgkin Lymphoma | Ascentage Pharma Group Inc. | Phase 1/2 | Unknown | NHL, Adult | 51 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05186012) |
| December 7, 2021 | NCT05147467 | Study of APG-2575 in Patients With Relapsed/Refractory CLL/SLL | Ascentage Pharma Group Inc. | Phase 2 | Recruiting | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | 75 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05147467) |
| July 16, 2021 | NCT04964518 | A Study of APG-2575 in Combination With Azacitidine in Patients With Acute Myeloid Leukemia (AML) | Ascentage Pharma Group Inc. | Phase 1/2 | Unknown | AML, Adult | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04964518) |
| July 1, 2021 | NCT04946864 | A Study to Investigate the Safety, Tolerability, of APG-2575 as a Single Agent or in Combination for Breast Cancer | Ascentage Pharma Group Inc. | Phase 1/2 | Suspended | Breast Cancer, Solid Tumor, Adult | 65 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04946864) |
| June 28, 2021 | NCT04942067 | APG-2575 in Combination With Novel Therapeutic Regimens in Subjects With Relapsed or Refractory Multiple Myeloma | Ascentage Pharma Group Inc. | Phase 1/2 | Unknown | Multiple Myeloma, Amyloidosis | 108 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04942067) |
| May 19, 2021 | NCT04893759 | A Study of Pelcitoclax (APG-1252) in Patients With Neuroendocrine Tumors | Ascentage Pharma Group Inc. | Phase 1 | Terminated | Neuroendocrine Tumors | 2 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04893759) |
| March 5, 2021 | NCT04785196 | APG-115 in Combination With PD-1 Inhibitor in Patients With Advanced Liposarcoma or Advanced Solid Tumors | Ascentage Pharma Group Inc. | Phase 1/2 | Recruiting | Liposarcoma, Advanced Solid Tumor | 95 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04785196) |
| December 19, 2020 | NCT04674514 | APG-2575 Monotherapy or in Combination With Lenalidomide/DXMS in Subjects With Relapsed or Refractory Multiple Myeloma | Ascentage Pharma Group Inc. | Phase 1/2 | Unknown | Multiple Myeloma | 48 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04674514) |
| November 25, 2020 | NCT04643405 | APG-1387 Plus Chemotherapy in Advanced Pancreatic Adenocarcinoma | Ascentage Pharma Group Inc. | Phase 1/2 | Terminated | Advanced Pancreatic Cancer | 21 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04643405) |

## By phase

| Phase | Trials |
| --- | --- |
| Early phase 1 | 1 |
| Phase 1 | 22 |
| Phase 1/2 | 16 |
| Phase 2 | 6 |
| Phase 3 | 7 |
| Not applicable | 1 |

## By status

| Status | Trials |
| --- | --- |
| Recruiting | 22 |
| Unknown | 11 |
| Completed | 10 |
| Terminated | 5 |
| Active not recruiting | 2 |
| Available | 1 |
| Withdrawn | 1 |
| Suspended | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Leukemia, Myeloid, Acute | 5 |
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 4 |
| Lymphoma, Non-Hodgkin | 4 |
| Leukemia, Myeloid, Chronic-Phase | 4 |
| Hematologic Neoplasms | 3 |
| Small Cell Lung Carcinoma | 3 |
| Leukemia, Lymphocytic, Chronic, B-Cell | 3 |
| Hepatitis B, Chronic | 2 |
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 2 |
| Multiple Myeloma | 2 |
| Waldenstrom Macroglobulinemia | 2 |
| Myelodysplastic Syndromes | 2 |
| Hepatitis B | 1 |
| Leukemia, Prolymphocytic, T-Cell | 1 |
| Neuroendocrine Tumors | 1 |
| Gastrointestinal Stromal Tumors | 1 |
| Primary Myelofibrosis | 1 |
| Thrombocytosis | 1 |
| Polycythemia Vera | 1 |
| Breast Neoplasms | 1 |
| Carcinoma, Non-Small-Cell Lung | 1 |
| Esophageal Neoplasms | 1 |
| Ovarian Neoplasms | 1 |
| Mesothelioma, Malignant | 1 |
| Leukemia, Myeloid | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Aluminum suppliers in the United States](https://specstream.ai/data/businesses/aluminum-suppliers/united-states)
- [Towing companies in the United States](https://specstream.ai/data/businesses/towing-companies/united-states)
- [Sake bars in the United States](https://specstream.ai/data/businesses/sake-bars/united-states)
- [Pediatric gastroenterology practices in the United States](https://specstream.ai/data/businesses/pediatric-gastroenterology-practices/united-states)
- [Marble and granite professional companies in the United States](https://specstream.ai/data/businesses/marble-and-granite-professional-companies/united-states)
- [Hostels in the United States](https://specstream.ai/data/businesses/hostels/united-states)
